Payment overview · 2025
General Payments
$170.93
9 reported records · 7 companies
Healthcare provider profile · identity verified
Jacqueline Valadez, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BOAZ, AL · NPI 1023577962
Verified facts
What the public records show
CMS Open Payments records show Jacqueline Valadez, DO received $170.93 in general payments during 2025 across 9 reported records.
Indivior Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $33.67 | 19.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.34 | 17.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.70 | 16.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.90 | 13.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.40 | 12.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 10.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.14 | 10.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.93 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $33.67 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 89 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1643 | 259 |
| Gabapentin | Gabapentin | 880 | 177 |
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 176 |
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 122 |
| Omeprazole | Omeprazole | 450 | 103 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 388 | 68 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 117 |
| Pregabalin | Pregabalin | 351 | 62 |
| Lisinopril | Lisinopril | 341 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 101 |
| Losartan Potassium | Losartan Potassium | 310 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 87 |
| Metformin Hcl | Metformin Hcl | 292 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 262 | 90 |
| Tizanidine Hcl | Tizanidine Hcl | 250 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 229 | 55 |
| Trazodone Hcl | Trazodone Hcl | 202 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 199 | 48 |
| Famotidine | Famotidine | 195 | 52 |
| Montelukast Sodium | Montelukast Sodium | 192 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 189 | 79 |
| Celecoxib | Celecoxib | 187 | 42 |
| Clonazepam | Clonazepam | 185 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 183 | 40 |
| Mounjaro | Tirzepatide | 183 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 180 | 50 |
| Furosemide | Furosemide | 179 | 57 |
| Meloxicam | Meloxicam | 174 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 29 |
| Buspirone Hcl | Buspirone Hcl | 152 | 43 |
| Methocarbamol | Methocarbamol | 140 | 38 |
| Trulicity | Dulaglutide | 138 | 33 |
| Ozempic | Semaglutide | 135 | 31 |
| Jardiance | Empagliflozin | 133 | 32 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 42 |
| Tramadol Hcl | Tramadol Hcl | 122 | 32 |
| Carvedilol | Carvedilol | 119 | 41 |
| Alendronate Sodium | Alendronate Sodium | 113 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 103 | 28 |
| Ezetimibe | Ezetimibe | 102 | 36 |
| Linzess | Linaclotide | 101 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 100 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 22 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 99 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 24 |
| Farxiga | Dapagliflozin Propanediol | 91 | 25 |
| Eliquis | Apixaban | 89 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 28 |
| Lidocaine | Lidocaine | 83 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 25 |
| Sertraline Hcl | Sertraline Hcl | 79 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 20 |
| Allopurinol | Allopurinol | 74 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 71 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 26 |
| Ibuprofen | Ibuprofen | 68 | 22 |
| Potassium Chloride | Potassium Chloride | 68 | 28 |
| Simvastatin | Simvastatin | 68 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 18 |
| Ondansetron Odt | Ondansetron | 64 | 26 |
| Fenofibrate | Fenofibrate | 59 | 19 |
| Mirtazapine | Mirtazapine | 59 | 14 |
| Baclofen | Baclofen | 58 | 12 |
| Glipizide | Glipizide | 58 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 13 |
| Spironolactone | Spironolactone | 56 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 55 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 18 |
| Promethazine Hcl | Promethazine Hcl | 52 | 20 |
| Naloxone Hcl | Naloxone Hcl | 50 | 43 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 11 |
| Topiramate | Topiramate | 50 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 19 |
| Alprazolam | Alprazolam | 47 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | 15 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 37 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 37 | 13 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Buprenorphine | Buprenorphine | 36 | 12 |
| Chlorthalidone | Chlorthalidone | 36 | 15 |
| Sucralfate | Sucralfate | 36 | 18 |
| Valacyclovir | Valacyclovir Hcl | 35 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 32 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Dayvigo | Lemborexant | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 14 |
| Nystatin | Nystatin | 21 | 11 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Cefdinir | Cefdinir | 20 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 20 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.93 · 9 records | Indivior Inc. | BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, Kerendia, NURTEC ODT, PAXLOVID, RECORLEV, SUBLOCADE, VERQUVO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error